价值导向检验医学时代的即时检验
即时检验(POCT)占全球实验室检测约25%,在危重症中分析性能可比甚至优于中心实验室。文章讨论POCT在准确性、可靠性及分析性能规范(APS)符合性方面的挑战,提出基于A型与B型被测量区分及POCT用于诊断和/或监测不同角色的科学组织建议。
要点
- POCT占全球实验室检测约25%,在危重症中可缩短周转时间(TAT)。
- 部分危重症被测量(如血气、电解质、血栓弹力图)POCT分析性能可比甚至优于中心实验室。
- 对B型被测量,改善诊断可及性、可接受分析性能与临床结局获益的平衡支持采用POCT。
核心结论
- 文章讨论POCT当前挑战,并提出基于A型与B型被测量区分及POCT用于诊断和/或监测不同角色的科学组织建议。
- 对B型被测量,改善诊断可及性、可接受分析性能与临床结局获益的平衡支持采用POCT,尤其在及时诊断和 linkage to care 关键的选择性场景。
研究设计与样本
- 本文为述评/观点文章,旨在讨论POCT当前挑战并提出基于科学和组织合理性的建议,未报告系统检索范围或样本量。
主要发现
- POCT过去三十年快速扩展,目前占全球所有实验室检测约25%。
- POCT最初因大幅缩短周转时间(TAT)而用于危重症,使临床决策更及时和治疗干预更迅速。
- 对危重症中选定的高临床价值被测量(如血气、电解质、血栓弹力图),POCT分析性能与中心实验室检测相当,有时甚至更优。
- POCT应用已从危重症扩展至初级保健、慢性病管理、社区服务、家庭护理及农村或偏远医疗场景,以改善实验室检测可及性。
- 对POCT结果的准确性和可靠性及其分析性能规范(APS)与当前推荐和临床要求的符合性存在担忧。
关键数值与推荐
- POCT目前占全球所有实验室检测约25%。
- 对危重症中选定的高临床价值被测量(如血气、电解质、血栓弹力图),POCT分析性能与中心实验室检测相当,有时甚至更优。
- 建议基于A型与B型被测量的区分以及POCT用于诊断和/或监测的不同角色,依据APS与既定推荐的符合程度制定。
临床怎么用
- 实验室专业人员应主导POCT的适当且循证采用,建立适合目的且灵活的质量控制策略。
- 应严格评估分析性能规范(APS),并确保从分析前到分析后的全过程全面监督与治理。
- 对B型被测量,在及时诊断和 linkage to care 关键的选择性场景可支持采用POCT。
局限性
- 本文为述评/观点文章,未报告系统检索范围或样本量。
- 对POCT结果的准确性和可靠性及其APS与当前推荐和临床要求的符合性存在担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Point-of-care testing (POCT) represents a breakthrough technology in laboratory medicine that has expanded rapidly over the past three decades. Today, it accounts for approximately 25 % of all laboratory tests performed worldwide. POCT was initially implemented in critical care settings due to its substantial reduction in turnaround time (TAT), enabling more timely clinical decision-making and prompt therapeutic interventions. For selected measurands of high clinical value in critical care settings (e.g., blood gases, electrolytes, thromboelastography), the analytical performance of POCT is comparable to - and in some cases even exceeds - that of central laboratory testing. Subsequently, the adoption of POCT has expanded beyond critical care to encompass primary care, chronic disease management, community-based services, home care, and rural or remote healthcare settings, with the aim of improving access to laboratory testing. However, concerns have been raised regarding the accuracy and reliability of POCT results, as well as the compliance of their analytical performance specifications (APS) with current recommendations and clinical requirements. The aim of this paper is to discuss the current challenges in POCT and to develop a proposal grounded in a robust scientific and organizational rationale. This proposal is based on the distinction between Type A and Type B measurands and on the different roles of POCT for diagnosis and/or monitoring, according to the degree of APS compliance with established recommendations. For Type B measurands, the balance between improved access to diagnostics, acceptable analytical performance, and demonstrated benefits in clinical outcomes supports the adoption of POCT, particularly in selected settings where timely diagnosis and linkage to care are critical. Laboratory professionals must lead the appropriate and evidence-based adoption of this technological breakthrough by establishing fit-for-purpose and flexible quality control strategies, rigorously evaluating analytical performance specifications, and ensuring comprehensive oversight and governance across the entire testing process - from pre-analytical to post-analytical phases.
引用
- Plebani M. Point-of-care testing in the era of value-based laboratory medicine. Clin Chem Lab Med. 2026. PMID: 41832136. doi:10.1515/cclm-2026-0309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。